synbio-pharma.com
Synbio
http://www.synbio-pharma.com/o-proekte/participants-of-the-project
Participants of the Project. Participants of the Project. Several leading Russian and international innovative companies are participating in project. The partners’ participation in the SynBio. Is a project aimed at creating innovative medicines, including what are known as Biobetters. joint venture is structured as follows (following the conclusion of the preliminary phase of the project and the entry of Rusnano):. When using the site materials reference is obligatory.
synbio-pharma.com
SynBio
http://www.synbio-pharma.com/portfel
At present our R&D portfolio includes nine first-in-class and BioBetters medicines based on three technological platforms – PolyXen, Histone and Gemacell. Development of Innovative Technologies for the SynBio Project. For treatment and/or prevention of anemia; contains a conjugate of EPO and polysialic acid as the active ingredient. For treatment of febrile neutropenia; contains a conjugate of G-CSF and polysialic acid as the active ingredient. When using the site materials reference is obligatory.
synbio-pharma.com
Multimedia library
http://www.synbio-pharma.com/press-tsentr/multimedia-library
When using the site materials reference is obligatory.
synbio-pharma.com
SynBio
http://www.synbio-pharma.com/o-proekte/about-the-project
Is a project aimed at creating innovative medicines, including what are known as Biobetters. This project, which has received financial support from Rusnano, is a collaborative effort of several Russian and international pharmaceutical companies. The largest private shareholder of SinBio is the Human Stem Cells Institute (HSCI), a leading Russian biotech company engaged in the development, introduction and commercialization of its own medicines based on stem cell, gene-therapy and post-genome tec...
synbio-pharma.com
News
http://www.synbio-pharma.com/news
HSCI Announces Terms of the Investment Agreement on SynBio Project. HSCI is the final signatory among the participating companies. When using the site materials reference is obligatory.
synbio-pharma.com
SynBio
http://www.synbio-pharma.com/issledovaniia-i-razrabotki/rd-facilities
Research and Development Centers. Xenetic (London, Great Britain) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs. Xenetic operate out of laboratory and office space at the London Bioscience Innovation Centre (LBIC), part of the Royal Veterinary College, London. When using the site materials reference is obligatory.
synbio-pharma.com
Synbio
http://www.synbio-pharma.com/o-proekte/corporate-governance
The Board of Directors is elected at a general meeting of the participants of the project. Of the Board’s seven members, three are appointed by Rusnano and four are selected from the candidates put forward by the other participants of the project. At present the three representatives of Rusnano are: Andrei Malyshev (Chairman of the Board), Deputy CEO, Rusnano; Olga Shpichko, Managing Director for Investment in Medical Programs, Rusnano; and, Roman Knyazev, Senior Investment Manager, Rusnano.
sinbio.org
Центры разработок
http://www.sinbio.org/issledovaniia-i-razrabotki/tsentry-razrabotok
Лондон, Великобритания), ведущая биофармацевтическая компания, специализируется на разработке фармацевтических препаратов направленного и пролонгированного действия, в том числе белковых лекарственных средств, вакцин и лекарств для лечения онкологических заболеваний. Лаборатория и офис Xenetic. Расположены в Лондонском биологическом научном инновационном центре (LBIC), который является частью Королевского ветеринарного колледжа в Лондоне. Разработки Липоксен защищены 9 международными патентами. Лаборатор...
sinbio.org
Портфель
http://www.sinbio.org/portfel
В настоящий момент в нашем R&D портфеле находится 9 препаратов классов First-in-class и BioBetters основанные на трех технологических платформах PolyXEN, Histone, Gemacell. Развитие технологических платформ проекта СинБио. Препарат для лечения и/или предотвращения анемии, содержащий конъюгат ЭПО и полисиаловой кислоты в качестве их активного вещества. Препарат для лечения фебрильной нейтропении, содержащий конъюгат Г-КСФ (GCSF) и полисиаловой кислоты в качестве активного вещества;. Препарат для лечения х...
